Herriot Tabuteau
$1.3B
Born
Jul 23, 1968
Age
57
Source of Wealth
Healthcare
Residence
New York, New York
Citizenship
United States
Marital Status
Married
Children
2
Education
Bachelor of Arts, Wesleyan; Medical Doctor, Yale School of Medicine
- Herriot Tabuteau founded Axsome Therapeutics in 2012 with the goal of developing life-changing treatments for the millions of patients living with brain disorders.
- Tabuteau owns 15% of Axsome, which he took public in 2015.
- Prior to founding the company, Tabuteau worked in healthcare finance, including as a partner at hedge fund Healthco/S.A.C. Capital.
- He is the inventor on more than 200 patents, including potential new medicines for depression, behavior disturbances in Alzheimer's disease and narcolepsy.
- Axsome's drug Symbravo (meloxicam and rizatriptan) received FDA approval in January 2025 for the acute treatment of migraines with or without auras.
- Its drug AXS-05 for the treatment of Alzheimer's disease agitation received a Breakthrough Therapy designation from the FDA in 2020. It now plans to submit a supplemental new drug application for it.
| Exchange | Ticker | Company Name | Number Of Shares | Share Price | Currency Code |
|---|